Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Monday, October 18, 2021

Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium

xlomafota13 shared this article with you from Inoreader

Am J Cancer Res. 2021 Sep 15;11(9):4070-4091. eCollection 2021.

ABSTRACT

Doxorubicin (DOX) is a highly effective chemotherapy agent that often causes cardiotoxicity. Despite a number of extensive studies, the risk for DOX cardiotoxicity remains unpredictable. The majority of the studies on DOX-induced cardiotoxicity have been focused on the effects on cardiomyocytes that lead to contractile dysfunction. The roles of systemic inflammation, endothelial injury and neutrophil recruitment, all induced by the DOX, are increasingly recognized as the mechanisms that trigger the development and progression of DOX-induced cardiomyopathy. This review explores recent data regarding the possible mechanisms and biomarkers of early subclinical DOX-associated cardiotoxicity.

PMID:34659877 | PMC:PMC8493405

View on the web

No comments:

Post a Comment